To investigate APTw CEST MRI signal characteristics in therapy-naive glioblastoma and their associations with clinical parameters and molecular features, highlighting their potential clinical significance.
Key Findings:
APTw CEST MRI can differentiate glioblastoma grades and IDH mutation status, which may influence treatment strategies.
The mesenchymal subtype shows limited benefit from extensive surgical resection compared to other subtypes, indicating a need for tailored approaches.
Interpretation:
APTw CEST MRI provides valuable insights into the molecular diversity of glioblastomas, potentially guiding treatment decisions and prognostic assessments, thereby enhancing patient management.
Limitations:
Study limited to a single center with a relatively small sample size, which may affect generalizability.
Potential biases in patient selection and imaging quality could influence the results and their interpretation.
Conclusion:
APTw CEST MRI may serve as a non-invasive biomarker for understanding tumor heterogeneity and guiding clinical management in glioblastoma, emphasizing the need for further validation in larger cohorts.
by Thomas Zeyen, Andreas Decker, Inga Krause, Florian Kroh, Julia Scheuble, Lea L. Friker, Torsten Pietsch, Sebastian Regnery, Alexander Effland, Johannes Weller, Niklas Schäfer, Alexander Radbruch, Ulrich Herrlinger, Daniel Paech
